Valuation: Codexis, Inc.

Market Cap 135M 118M 110M 101M 189M 12.96B 192M 1.3B 510M 6.37B 505M 494M 22.02B P/E 2026 *
-3.83x
P/E 2027 * -5.14x
Enterprise Value 135M 118M 110M 101M 189M 12.96B 192M 1.3B 510M 6.37B 505M 494M 22.02B EV / Sales 2026 *
1.82x
EV / Sales 2027 * 1.51x
Free-Float
92.59%
Yield 2026 *
-
Yield 2027 * -
1 day-25.63%
1 week-33.93%
Current month-34.51%
1 month-34.80%
3 months-43.51%
6 months-11.90%
Current year-9.20%
1 week 1.44
Extreme 1.44
2.3
1 month 1.44
Extreme 1.44
2.7
Current year 0.96
Extreme 0.9583
2.98
1 year 0.96
Extreme 0.9583
3.87
3 years 0.96
Extreme 0.9583
6.08
5 years 0.96
Extreme 0.9583
42.01
10 years 0.96
Extreme 0.9583
42.01
Manager TitleAgeSince
Chief Executive Officer 59 07/11/2025
Director of Finance/CFO 59 30/09/2024
Chief Tech/Sci/R&D Officer 56 05/05/2020
Director TitleAgeSince
Director/Board Member 66 01/03/2016
Director/Board Member 59 07/11/2025
Chairman 66 -
Date Insider Type Main position Quantity % Market Cap.
6/17/26 A Free

Director

66,350 0.0730%
6/17/26 A Free

Director

66,350 0.0730%
6/17/26 A Free

Chairman

66,350 0.0730%
Change 5-day change 1-year change 3-year change Capi.($)
-25.63%-33.93%-54.32%-58.89% 135M
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average -2.36%-0.04%+42.83%+88.90% 24.54B
Weighted average by Cap. +0.46%+0.91%+75.24%+136.53%

Financials

2026 *2027 *
Net sales 74.1M 65.08M 60.52M 55.54M 104M 7.14B 106M 719M 281M 3.51B 278M 272M 12.13B 88.93M 78.11M 72.64M 66.65M 125M 8.56B 127M 863M 337M 4.21B 334M 327M 14.56B
Net income -35.29M -31M -28.83M -26.45M -49.7M -3.4B -50.47M -342M -134M -1.67B -132M -130M -5.78B -26.56M -23.33M -21.69M -19.91M -37.4M -2.56B -37.98M -258M -101M -1.26B -99.7M -97.55M -4.35B
Net Debt - -
Logo Codexis, Inc.
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Employees
146
Date Price Change Volume
24/07/26 $1.480 -25.63% 10,376,854
23/07/26 $1.990 -3.40% 848,452
22/07/26 $2.060 -6.36% 773,937
21/07/26 $2.200 -0.45% 1,512,256
20/07/26 $2.210 -1.34% 506,418
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.480USD
Average target price
6.583USD
Spread / Average Target
+344.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CDXS Stock